A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Non Small Cell Lung Cancer Clinical Trial

Official title:

A Phase II/III Clinical Study on the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Perioperative Treatment of Resectable Stage II/III Non Small Cell Lung Cancer.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05913089
• Other study ID #: TQB2450-II/III-01
• Status: Recruiting
• Phase: Phase 2
• Start date: June 14, 2023
• Est. completion date: December 2026

Study information

• Verified date: December 2022
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: Shugeng Gao, Doctor
• Phone: +86 13901362568
• Email: 13901362568[@]139.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a clinical study on the efficacy and safety of TQB2450 injection combined with chemotherapy or anlotinib hydrochloride capsule in the perioperative treatment of resectable non-small cell lung cancer. The part I study was planned to enroll 58 subjects, 1:1 randomized into two cohorts. The treatment regimen was as follows: Cohort 1: 3-4 cycles of TQB2450 combined with chemotherapy, surgery should be performed 4-6 weeks after the last administration, and TQB2450 therapy should be continued for 1 year after surgery. Cohort 2: 4 cycles of TQB2450 combined with 3 cycles of anlotinib hydrochloride capsule. Surgery was performed 4-6 weeks after the last dose and continued for 1 year starting 4 weeks after surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 58
• Est. completion date: December 2026
• Est. primary completion date: June 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• patients with stage II-IIIB (T3N2M0 only) Non-Small Cell Lung Carcinoma (NSCLC) and determined to be eligible for curable R0 excision, after pathologic diagnosis of puncture specimens;

• =18 years old (calculated on the date of signing the informed consent); Both men and women; Eastern Cooperative Oncology Group (ECOG) score 0~1; Predicted survival =3 months;

• Have at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria within 28 days prior to initiation of treatment;

• Has not received systemic antitumor therapy, including radiotherapy, chemotherapy and immunotherapy;

• Agree to provide fresh or 6 month tumor tissue for programmed death ligand -1 (PD-L1) testing.

• Major organs are functioning well.

• Women of reproductive age should agree that they must use effective birth control during the study period and for 6 months after the study, and that a negative serum or urine pregnancy test occurred within 7 days prior to study enrollment; Men should agree that effective contraception must be used during the study period and for 6 months after the study period ends.

• The subjects voluntarily joined the study and signed the informed consent with good compliance.

Exclusion Criteria:

• Present or complication with other malignancies within 5 years.

• Subjects are known to have genetic abnormalities with approved targeted drug therapy.

• Cirrhosis, active hepatitis;

• Cardio-cerebrovascular abnormalities;

• Subjects with severe active infection within 4 weeks prior to initiation of study treatment; Or unexplained fever >38.0 ? occurred during screening and before first administration;

• Patients with active tuberculosis within 1 year prior to enrollment;

• Immunodeficiency disease;

• History of active autoimmune disease or autoimmune disease;

• Preparing for or having previously received an organ transplant, or having received a hematopoietic stem cell transplant within 60 days prior to initial medication, or having a significant host transplant response;

• Patients who required immunosuppressive, systemic, or absorbable topical hormone therapy for immunosuppressive purposes and continued use within two weeks prior to randomization

• Severe infection of grade 4 or higher occurred within 1 year prior to initiation of study therapy;

• Severe lung disease;

• History of pituitary or adrenal dysfunction;

• History of severe mental disorder;

• History of drug abuse, alcoholism or drug use;

• Participated in clinical trials of other drugs within 30 days;

• History of live attenuated vaccine vaccination within 28 days prior to randomization or planned live attenuated vaccine vaccination during the study period;

• Received Chinese patent drugs with anti-tumor indications specified in the National Medical Product Administration approved drug package inserts within 2 weeks prior to initiation of administration

• Had major surgery within 4 weeks prior to initiation of medication;

• Other severe, acute, or chronic medical conditions or laboratory abnormalities that, in the investigator's opinion, may increase the risks associated with study participation or may interfere with the interpretation of the study results, or are otherwise unsuitable for participation in the clinical study;

• The compliance of patients to participate in this clinical study is estimated to be insufficient.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• TQB2450 injection + Chemotherapy
TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1). Chemotherapy is a systematic treatment that kill fast growing cells.
• TQB2450 injection + Anlotinib Hydrochloride Capsule
TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1). Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing
China	Beijing Chaoyang Hospital, Capital Medical University	Beijing	Beijing
China	Beijing Chest Hospital, Capital Medical University	Beijing	Beijing
China	Cancer Hospital of Chinese Academy of Medical Sciences	Beijing	Beijing
China	Fujian Medical University Union Hospital	Fuzhou	Fujian
China	Shanghai Chest Hospital	Shanghai	Shanghai
China	Shanxi Cancer Hospital	Taiyuan	Shanxi
China	Tianjin Chest Hospital	Tianjin	Tianjin
China	Tianjin Medical University General Hospital	Tianjin	Tianjin
China	Weifang People's Hospital	Weifang	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major pathologic response (MPR)	MPR defined as the percentage of subjects with a residual surviving tumor less than or equal to 10% after surgery.	Baseline up to 60 months.
Secondary	Overall survival (OS)	From randomization to the time of death from any cause.	Baseline up to 60 months.
Secondary	2/3 year OS rate	The ratio of two-year survival to three-year survival.	Baseline up to 36 months.
Secondary	Event free survival (EFS) assessed by the investigator.	From the time of randomization to the occurrence of a predetermined event, including death, disease progression, change to chemotherapy, change to chemotherapy, addition of other treatments, occurrence of fatal or intolerable side effects, etc.	Baseline up to 60 months.
Secondary	Disease free survival (DFS) assessed by Blinded Independent Central Review (BICR)	The time from randomization to the onset of tumor recurrence or death from any cause.	Baseline up to 60 months.
Secondary	Pathological complete response (pCR)	Ratio of patients with no residual cancer cells found in the pathological examination after treatment.	Baseline up to 4 months.
Secondary	R0 resection rate	The proportion of subjects who could undergo R0 resection, which is one of the surgery-related end points.	Baseline up to 4 months.
Secondary	Surgical delay rate	The proportion of subjects who could not undergo surgery in time after neoadjuvant therapy.	Baseline up to 4 months.
Secondary	Pathological downgrading rate	The proportion of patients with reduced lung cancer stage determined by pathological results after surgery.	Baseline up to 4 months.